Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study

The Improvement Effect of Catheter Ablation on Functional Mitral Regurgitation in Patients With Persistent Atrial Fibrillation and the Construction and Validation of a Predictive Model: A Multicenter Prospective Cohort Study

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07096219

Enrollment

556

Registered

2025-07-31

Start date

2024-12-31

Completion date

2027-12-30

Last updated

2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AF Ablation Patients With Moderate+ FMR and Persistent AF

Brief summary

Mitral Regurgitation (MR) is the most prevalent type of valvular heart disease in clinical practice, with an average prevalence of approximately 1% in populations with moderate-to-severe or worse MR, which increases significantly with age. Functional MR (FMR) is one subtype of MR and can be further classified into atrial FMR, ventricular FMR, and mixed FMR based on its underlying mechanisms. Pathophysiologically, FMR is closely associated with atrial fibrillation (AF) and heart failure (HF). Studies suggest that catheter ablation for AF may improve FMR in some patients and reverse left atrial (LA) and left ventricular (LV) remodeling. However, there is currently a lack of precise and effective indicators or predictive models to determine the evolution of FMR after AF ablation in both domestic and international research. This study aims to conduct a multicenter prospective cohort study, enrolling patients with moderate or worse FMR and persistent AF undergoing ablation. Using postoperative 3-month FMR improvement as the primary outcome, we will employ big data mining and multimodal analysis to construct a predictive model for FMR progression after AF ablation and validate it through prospective multicenter testing. The findings will provide a scientific basis for clinical decision-making and precision medicine in this patient population.

Interventions

PROCEDURECatheter Ablation

A minimally invasive procedure that delivers energy through catheters to destroy abnormal cardiac tissue causing arrhythmias.

DIAGNOSTIC_TESTultrasonic cardiography (UCG)

Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surfa

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Aged 18-75 years 2. Diagnosis of functional mitral regurgitation (FMR) by transthoracic echocardiography (TTE) and/or transesophageal echocardiography (TEE) with combined qualitative and quantitative assessment, demonstrating moderate or worse regurgitation (≥ grade 2+) 3. Persistent atrial fibrillation (AF) with successful catheter ablation 4. Signed informed consent with commitment to regular follow-up for ≥1 year

Exclusion criteria

1. Acute or chronic degenerative mitral regurgitation (DMR) from any etiology 2. Paroxysmal or permanent atrial fibrillation 3. Planned repeat ablation for AF recurrence 4. Concomitant moderate/severe valvular disease (e.g., mitral stenosis, aortic stenosis/regurgitation, pulmonary stenosis/regurgitation) 5. Prior valvular surgery/intervention 6. History of open-heart surgery 7. Severe pulmonary hypertension (PASP \>70 mmHg) refractory to medical therapy 8. Left atrial diameter ≥60 mm (diastolic phase) on echocardiography 9. Uncontrolled hyperthyroidism 10. Intracardiac mass/thrombus/vegetation 11. Significant shunts (ASD/VSD/PDA) 12. Hypertrophic obstructive cardiomyopathy 13. Active severe infection/sepsis (including infective endocarditis) 14. Scheduled CRT/CRT-D/CCM implantation 15. Untreated critical CAD (e.g., ≥70% stenosis in proximal/mid LAD/LCX/RCA requiring revascularization) or concomitant major cardiovascular surgery needs 16. End-stage heart failure (ACC/AHA Stage D) requiring mechanical support/transplant listing 17. Severe hepatic dysfunction (acute liver failure/decompensated cirrhosis, Child-Pugh C) 18. Severe renal impairment (CKD 5: eGFR\<15 mL/min or dialysis) 19. Hemodynamic instability (SBP\<90 mmHg/MAP\<70 mmHg with hypoperfusion \[urine output\<30 mL/h\]) 20. Contraindications to antithrombotics: Active bleeding (GI/intracranial/visceral), bleeding disorders (hemophilia/ITP/leukemia etc.), severe hematologic abnormalities (platelets\<20×10⁹/L, spontaneous INR\>3) 21. Uncontrolled autoimmune/connective tissue disease 22. Acute MI within 4 weeks 23. Stroke within 30 days 24. Acute peptic ulcer/upper GI bleeding within 3 months 25. Pregnancy/lactation 26. Declined informed consent 27. Life expectancy \<1 year 28. Poor compliance (anticipated inability to complete follow-up) 29. Concurrent participation in conflicting clinical trials 30. Other investigator-determined exclusions.

Design outcomes

Primary

Measure	Time frame	Description
The primary endpoint was MR improvement at 3 months post-procedure.	From the operation day to 3 months after operation.	MR improvement was defined as a reduction in regurgitation severity by ≥1 grade on 3-month post-ablation transthoracic echocardiography (TTE) compared to baseline. Absence of improvement or worsening was categorized as non-improvement.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORYangxin Chen, PhD

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026